Skip to main content

Viral hepatitis in China and India

It has been three years since the advent of highly effective direct acting antiviral drugs that can cure hepatitis C in >90% of the cases. There has also been tremendous progress in understanding and combating this infection including through major policy developments. The most notable achievement during this time has been the two WHO resolutions on viral hepatitis and a forthcoming Global Health Sector Strategy on Viral Hepatitis. This commissioned supplement includes an array of articles on various aspects of hepatitis B and C prevention, treatment and care in China and India.

Publication charges for this collection were funded by the Bristol-Meyer Squibb Foundation. Articles have undergone the journal's standard peer-review process overseen by the Editor-in-Chief, Jeffrey V Lazarus, who declares no competing interests. Both Prof. Lazarus and Guest Editor Kelly Safreed-Harmon were responsible for setting the scope of the series, for identifying suitable authors and encouraging appropriate submissions. Kelly Safreed-Harmon was not involved in the peer-process and declares support from Bristol-Meyer Squibb Foundation.

  1. India is home to one in 14 of all chronic hepatitis B virus (HBV) cases, meaning that it is important to develop HBV interventions that are applicable in the Indian context. Vaccination is the foremost tool fo...

    Authors: Gourdas Choudhuri, Rajesh Ojha, T. S. Negi, Varun Gupta, Shipra Saxena, Arundhati Choudhuri, Sanjoy Pal, Jui Choudhuri and Alok Sangam
    Citation: Hepatology, Medicine and Policy 2017 2:10

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:11

  2. India has a high burden of disease from hepatitis B virus (HBV), with 3.7 % point-prevalence, as well as from hepatitis C virus (HCV), with 1–1.5 % prevalence. Societal ignorance about HBV and HCV in India lim...

    Authors: Partha Sarathi Mukherjee, Eliza Dutta, Dipesh Kr. Das, Shatabdi Ghosh, Suvadip Neogi and Arka Sarkar
    Citation: Hepatology, Medicine and Policy 2016 2:6

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:13

  3. The Hepatitis C virus (HCV) is very common among people who inject drugs (PWID), yet PWID in India have suboptimal access to HCV testing and treatment. This study sought to identify HCV risk factors among male...

    Authors: Ruchi Sogarwal, Varada Madge, Pratyush Bishi, Apam Woleng and Rishi Garg
    Citation: Hepatology, Medicine and Policy 2016 1:1
  4. More than 17 million people in India are chronically infected with the hepatitis B virus (HBV). Approximately one million of the 26 million children born in India annually will develop chronic HBV infection in...

    Authors: Swati Jha, Divyesh Devaliya, Susan Bergson and Shripad Desai
    Citation: Hepatology, Medicine and Policy 2016 1:5
  5. Hepatitis C virus (HCV) imposes a considerable disease burden in China, with at least 10 million people chronically infected. Little is known about the financial impact of the HCV epidemic, nor about the exten...

    Authors: Hai-yang Zhou, Shuang Liu, Su-jun Zheng, Xiao-xia Peng, Yu Chen, Carol Duan, Qing-fen Zheng, Zhao Wang and Zhong-ping Duan
    Citation: Hepatology, Medicine and Policy 2016 1:7
  6. This article describes hepatitis B-related knowledge, attitudes and practices after completion of the Gateway to Care campaign, a citywide public health education program that targeted city residents, health c...

    Authors: Chari Cohen, Alison A. Evans, Peixin Huang, W. Thomas London, Joan M. Block and Gang Chen
    Citation: Hepatology, Medicine and Policy 2016 1:4